Search Results - "Obasaju, Coleman K"

PointBreak: A Randomized Phase III Study of Pemetrexed Plus Carboplatin and Bevacizumab Followed by Maintenance Pemetrexed and Bevacizumab Versus Paclitaxel Plus Carboplatin and Bevacizumab Followed by Maintenance Bevacizumab in Patients With Stage IIIB or IV Nonsquamous Non–Small-Cell Lung Cancer by PATEL, Jyoti D, SOCINSKI, Mark A, GUBA, Susan C, JINGYI LIU, FRIMODT-MOLLER, Bente, JOHN, William J, OBASAJU, Coleman K, PENNELLA, Eduardo J, BONOMI, Philip, GOVINDAN, Ramaswamy, GARON, Edward B, REYNOLDS, Craig H, SPIGEL, David R, OLSEN, Mark R, HERMANN, Robert C, JOTTE, Robert M, BECK, Thaddeus, RICHARDS, Donald A

“…PointBreak (A Study of Pemetrexed, Carboplatin and Bevacizumab in Patients With Nonsquamous Non-Small Cell Lung Cancer) compared the efficacy and safety of…”
Get full text

Phase III Study of Immediate Compared With Delayed Docetaxel After Front-Line Therapy With Gemcitabine Plus Carboplatin in Advanced Non–Small-Cell Lung Cancer by FIDIAS, Panos M, DAKHIL, Shaker R, MARCINIAK, Martin, GILL, John, SCHILLER, Joan H, LYSS, Alan P, LOESCH, David M, WATERHOUSE, David M, BROMUND, Jane L, RUQIN CHEN, HRISTOVA-KAZMIERSKI, Maria, TREAT, Joseph, OBASAJU, Coleman K

“…Gemcitabine plus carboplatin (GC) is active as front-line treatment for advanced non-small-cell lung cancer (NSCLC). For patients without progression, timing…”
Get full text

Multicenter Phase II Trial of Neoadjuvant Pemetrexed Plus Cisplatin Followed by Extrapleural Pneumonectomy and Radiation for Malignant Pleural Mesothelioma by KRUG, Lee M, PASS, Harvey I, OBASAJU, Coleman K, VOGELZANG, Nicholas J, RUSCH, Valerie W, KINDLER, Hedy L, SUGARBAKER, David J, ROSENZWEIG, Kenneth E, FLORES, Raja, FRIEDBERG, Joseph S, PISTERS, Katherine, MONBERG, Matthew

“…Neoadjuvant pemetrexed plus cisplatin was administered, followed by extrapleural pneumonectomy (EPP) and hemithoracic radiation (RT), to assess the feasibility…”
Get full text

PRONOUNCE: randomized, open-label, phase III study of first-line pemetrexed + carboplatin followed by maintenance pemetrexed versus paclitaxel + carboplatin + bevacizumab followed by maintenance bevacizumab in patients ith advanced nonsquamous non-small-cell lung cancer by Zinner, Ralph G, Obasaju, Coleman K, Spigel, David R, Weaver, Robert W, Beck, J Thaddeus, Waterhouse, David M, Modiano, Manuel R, Hrinczenko, Borys, Nikolinakos, Petros G, Liu, Jingyi, Koustenis, Andrew G, Winfree, Katherine B, Melemed, Symantha A, Guba, Susan C, Ortuzar, Waldo I, Desaiah, Durisala, Treat, Joseph A, Govindan, Ramaswamy, Ross, Helen J

“…PRONOUNCE compared the efficacy and safety of pemetrexed+carboplatin followed by pemetrexed (Pem+Cb) with paclitaxel+carboplatin+bevacizumab followed by…”
Get more information

Phase III Study of Pemetrexed Plus Carboplatin Compared With Etoposide Plus Carboplatin in Chemotherapy-Naive Patients With Extensive-Stage Small-Cell Lung Cancer by SOCINSKI, Mark A, SMIT, Egbert F, JASSEM, Jacek, DEDIU, Mircea, SHENGYAN HONG, VISSEREN-GRUL, Carla, HANAUSKE, Axel-Rainer, OBASAJU, Coleman K, GUBA, Susan C, THATCHER, Nick, LORIGAN, Paul, KONDURI, Kartik, RECK, Martin, SZCZESNA, Aleksandra, BLAKELY, Johnetta, SERWATOWSKI, Piotr, KARASEVA, Nina A, CIULEANU, Tudor

“…Following a phase II trial in which pemetrexed-platinum demonstrated similar activity to that of historical etoposide-platinum controls, a phase III study was…”
Get full text

Phase II Study of Pemetrexed for Second-Line Treatment of Transitional Cell Cancer of the Urothelium by Sweeney, Christopher J, Roth, Bruce J, Kabbinavar, Fairooz F, Vaughn, David J, Arning, Michael, Curiel, Rafael E, Obasaju, Coleman K, Wang, Yanping, Nicol, Steven J, Kaufman, Donald S

“…To assess the antitumor activity and toxicity of pemetrexed as second-line chemotherapy in patients with locally advanced or metastatic transitional cell…”
Get full text

Pemetrexed Plus Gemcitabine As First-Line Chemotherapy for Patients With Peritoneal Mesothelioma: Final Report of a Phase II Trial by SIMON, George R, VERSCHRAEGEN, Claire F, GILL, John, OBASAJU, Coleman K, KINDLER, Hedy L, JÄNNE, Pasi A, LONGER, Corey J, DOWLATI, Afshin, GADGEEL, Shirish M, KELLY, Karen, KALEMKERIAN, Gregory P, TRAYNOR, Anne M, PENG, Guangbin

“…Pemetrexed in combination with cisplatin is approved for the treatment of pleural mesothelioma and is active in malignant peritoneal mesothelioma (MPeM)…”
Get full text

Cetuximab plus platinum-based chemotherapy in head and neck squamous cell carcinoma: a randomized, double-blind safety study comparing cetuximab produced from two manufacturing processes using the EXTREME study regimen by Soulières, Denis, Aguilar, Jose Luis, Chen, Eric, Misiukiewicz, Krzysztof, Ernst, Scott, Lee, Hyun Jung, Bryant, Katherine, He, Shuang, Obasaju, Coleman K, Chang, Shao-Chun, Chin, Steve, Adkins, Douglas

“…Cetuximab, in combination with platinum chemotherapy plus 5-fluoruracil (5-FU), is approved for the first-line treatment of recurrent/metastatic squamous cell…”
Get full text

Phase III Study of Gemcitabine and Cisplatin With or Without Aprinocarsen, a Protein Kinase C-Alpha Antisense Oligonucleotide, in Patients With Advanced-Stage Non–Small-Cell Lung Cancer by PAZ-ARES, Luis, DOUILLARD, Jean-Yves, LAHN, Michael, GANDARA, David R, KORALEWSKI, Piotr, MANEGOLD, Christian, SMIT, Egbert F, REYES, José Miguel, CHANG, Gee-Chen, JOHN, William J, PETERSON, Patrick M, OBASAJU, Coleman K

“…To determine whether aprinocarsen, an antisense oligonucleotide directed against protein kinase C-alpha, when added to the chemotherapy regimen of gemcitabine…”
Get full text

Randomized Phase II Trial of Pemetrexed Combined With Either Cisplatin or Carboplatin in Untreated Extensive-Stage Small-Cell Lung Cancer by SOCINSKI, Mark A, WEISSMAN, Charles, HART, Lowell L, BECK, J. Thaddeus, CHOKSI, Janak K, HANSON, John P, PRAGER, Diane, MONBERG, Matthew J, ZHISHEN YE, OBASAJU, Coleman K

“…Given the activity and tolerability of pemetrexed/platinum combinations in non-small-cell lung cancer, and the success of novel therapeutic strategies employed…”
Get full text

Impact of preoperative chemotherapy on pulmonary function tests in resectable early-stage non-small cell lung cancer by Rivera, M Patricia, Detterbeck, Frank C, Socinski, Mark A, Moore, Dominic T, Edelman, Martin J, Jahan, Thierry M, Ansari, Rafat H, Luketich, James D, Peng, Guangbin, Monberg, Matthew, Obasaju, Coleman K, Gralla, Richard J

“…Several chemotherapy agents, including gemcitabine and paclitaxel, have been reported to cause interstitial pneumonitis. The incidence of pulmonary toxicity…”
Get more information

Randomized phase II trial of cisplatin, etoposide, and radiation followed by gemcitabine alone or by combined gemcitabine and docetaxel in stage III A/B unresectable non-small cell lung cancer by Movsas, Benjamin, Langer, Corey J, Ross, Helen J, Wang, Luhua, Jotte, Robert M, Feigenberg, Steve, Xu, Feng, Huang, Chao H, Monberg, Matthew J, Obasaju, Coleman K

“…Southwest Oncology Group 9504 demonstrated the feasibility and potential benefit of docetaxel consolidation after etoposide, cisplatin, and radiotherapy in…”
Get more information

Phase II Study of Pemetrexed-Gemcitabine Combination in Patients with Advanced-Stage Non-Small Cell Lung Cancer by MONNERAT, Christian, LE CHEVALIER, Thierry, ETTINGER, David S, KELLY, Karen, OBASAJU, Coleman K, BRAHMER, Julie, NOVELLO, Silvia, NAKAMURA, Takashi, LIEPA, Astra M, BOZEC, Laurence, BUNN, Paul A

“…Purpose: Cisplatin is one of the most active agents for the treatment of non-small cell lung cancer (NSCLC). It is also known for significant toxicity, which…”
Get full text

Rash management and treatment persistence of cancer patients treated with epidermal growth factor receptor inhibitors in the Truven MarketScan® research database by Chen, Lei, Brown, Jacqueline, Marmaduke, Dale Quentin, Mayo, Carlos, Grau, Gerrit, Lau, Yiu-Keung, Obasaju, Coleman K

“…Purpose Rash toxicity is a common, expected class effect of epidermal growth factor receptor (EGFR) inhibitors. Although rash management is practiced, it is…”
Get full text

Pemetrexed Continuation Maintenance Phase 3 Trials in Nonsquamous, Non–Small-Cell Lung Cancer: Focus on 2-Year Overall Survival and Continuum of Care by Patel, Jyoti D., Paz-Ares, Luis, Zinner, Ralph G., Barlesi, Fabrice, Koustenis, Andrew G., Obasaju, Coleman K.

“…Although lung cancer prognosis remains poor for most patients, treatments developed in the past 2 decades have extended survival for many. For those with…”
Get full text

Comparison of pemetrexed plus cisplatin with other first-line doublets in advanced non-small cell lung cancer (NSCLC): A combined analysis of three phase 3 trials by Treat, Joseph, Scagliotti, Giorgio V, Peng, Guangbin, Monberg, Matthew J, Obasaju, Coleman K, Socinski, Mark A

“…Abstract Introduction In a first-line study of advanced NSCLC, pemetrexed–cisplatin was more effective among patients with adenocarcinoma and large-cell…”
Get full text

Pemetrexed in head and neck cancer: A systematic review by Argiris, Athanassios, Pennella, Eduardo, Koustenis, Andrew, Hossain, Anwar M, Obasaju, Coleman K

“…Summary Pemetrexed has been evaluated as a novel chemotherapeutic for head and neck cancer (HNC). In this review, we examined the efficacy and tolerability of…”
Get full text

A retrospective analysis of outcomes by age in a three-arm phase III trial of gemcitabine in combination with carboplatin or paclitaxel vs. paclitaxel plus carboplatin for advanced non-small cell lung cancer by Ansari, Rafat H, Socinski, Mark A, Edelman, Martin J, Belani, Chandra P, Gonin, René, Catalano, Robert B, Marinucci, Donna M, Comis, Robert L, Obasaju, Coleman K, Chen, Ruqin, Monberg, Matthew J, Treat, Joseph

“…Abstract Purpose Sufficient data are currently unavailable to assist in defining suitable regimens for patients ≥70 years with advanced non-small cell lung…”
Get full text

Open-Label Study of Pemetrexed Alone or in Combination with Cisplatin for the Treatment of Patients with Peritoneal Mesothelioma: Outcomes of an Expanded Access Program by Jänne, Pasi A., Wozniak, Antoinette J., Belani, Chandra P., Keohan, Mary-Louise, Ross, Helen J., Polikoff, Jonathan A., Mintzer, David M., Taylor, Loretta, Ashland, Joseph, Ye, Zhishen, Monberg, Matthew J., Obasaju, Coleman K.

“…BACKGROUND: To date, few large studies have been reported of patients with peritoneal mesothelioma, and treatment of this disease has been largely extrapolated…”
Get full text

Outcomes associated with brain metastases in a three-arm phase III trial of gemcitabine-containing regimens versus paclitaxel plus carboplatin for advanced non-small cell lung cancer by Edelman, Martin J, Belani, Chandra P, Socinski, Mark A, Ansari, Rafat H, Obasaju, Coleman K, Chen, Ruqin, Monberg, Matthew J, Treat, Joseph

“…Brain metastases (BMs) are a common complication of non-small cell lung cancer (NSCLC). Because of historical data indicating a poor prognosis for patients…”
Get more information